Table of Contents
International Journal of Proteomics
Volume 2012, Article ID 510397, 11 pages
http://dx.doi.org/10.1155/2012/510397
Research Article

Seven-Signal Proteomic Signature for Detection of Operable Pancreatic Ductal Adenocarcinoma and Their Discrimination from Autoimmune Pancreatitis

1Institute for Advanced Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan
2Division of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan
3Division of Epidemiology and Prevention, Aichi Cancer Center, Nagoya 464-8681, Japan
4Division of Research and Development, Oncomics Co., Ltd, Nagoya 464-0858, Japan
5Division of Surgical Oncology, Department of Surgery, Nagoya University Hospital, Nagoya 466-8550, Japan
6Department of Gastroenterology, Nagoya University Hospital, Nagoya 466-8550, Japan
7Department of Gastroenterology, Aichi Cancer Center, Nagoya 464-8681, Japan

Received 27 January 2012; Accepted 9 March 2012

Academic Editor: Visith Thongboonkerd

Copyright © 2012 Kiyoshi Yanagisawa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. http://ganjoho.ncc.go.jp/public/statistics/backnumber/2009_en.html.
  2. http://www.cancer.gov/cancertopics/types/pancreatic.
  3. M. Yamamoto, O. Ohashi, and Y. Saitoh, “Japan pancreatic cancer registry: current status,” Pancreas, vol. 16, no. 3, pp. 238–242, 1998. View at Google Scholar · View at Scopus
  4. M. Goggins, M. Canto, and R. Hruban, “Can we screen high-risk individuals to detect early pancreatic carcinoma?” World Journal of Surgical Oncology, vol. 74, no. 4, pp. 243–248, 2000. View at Google Scholar
  5. R. A. Abrams, L. B. Grochow, A. Chakravarthy et al., “Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA 19-9 levels,” International Journal of Radiation Oncology Biology Physics, vol. 44, no. 5, pp. 1039–1046, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. R. E. Ritts and H. A. Pitt, “CA 19-9 in pancreatic cancer,” Surgical Oncology Clinics of North America, vol. 7, no. 1, pp. 93–101, 1998. View at Google Scholar · View at Scopus
  7. H. Hamano, S. Kawa, A. Horiuchi et al., “High serum IgG4 concentrations in patients with sclerosing pancreatitis,” The New England Journal of Medicine, vol. 344, no. 10, pp. 732–738, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. D. L. Finkelberg, D. Sahani, V. Deshpande, and W. R. Brugge, “Autoimmune pancreatitis,” The New England Journal of Medicine, vol. 355, no. 25, pp. 2670–2676, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Pickartz, J. Mayerle, and M. M. Lerch, “Autoimmune pancreatitis,” Nature Clinical Practice Gastroenterology & Hepatology, vol. 4, no. 6, pp. 314–323, 2007. View at Google Scholar
  10. F. Taguchi, B. Solomon, V. Gregorc et al., “Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study,” Journal of the National Cancer Institute, vol. 99, no. 11, pp. 838–846, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. E. F. Petricoin, A. M. Ardekani, B. A. Hitt et al., “Use of proteomic patterns in serum to identify ovarian cancer,” The Lancet, vol. 359, no. 9306, pp. 572–577, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. B. L. Adam, Y. Qu, J. W. Davis et al., “Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men,” Cancer Research, vol. 62, no. 13, pp. 3609–3614, 2002. View at Google Scholar · View at Scopus
  13. K. Yanagisawa, Y. Shyr, B. J. Xu et al., “Proteomic patterns of tumour subsets in non-small-cell lung cancer,” The Lancet, vol. 362, no. 9382, pp. 433–439, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Yanagisawa, S. Tomida, Y. Shimada, Y. Yatabe, T. Mitsudomi, and T. Takahashi, “A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer,” Journal of the National Cancer Institute, vol. 99, no. 11, pp. 858–867, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. V. G. Tusher, R. Tibshirani, and G. Chu, “Significance analysis of microarrays applied to the ionizing radiation response,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 9, pp. 5116–5121, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. T. R. Golub, D. K. Slonim, P. Tamayo et al., “Molecular classification of cancer: class discovery and class prediction by gene expression monitoring,” Science, vol. 286, no. 5439, pp. 531–527, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Simon, M. D. Radmacher, K. Dobbin, and L. M. McShane, “Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification,” Journal of the National Cancer Institute, vol. 95, no. 1, pp. 14–18, 2003. View at Google Scholar · View at Scopus
  18. M. B. Eisen, P. T. Spellman, P. O. Brown, and D. Botstein, “Cluster analysis and display of genome-wide expression patterns,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 25, pp. 14863–14868, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Dupuy and R. M. Simon, “Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting,” Journal of the National Cancer Institute, vol. 99, no. 2, pp. 147–157, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Ghazale, S. T. Chari, T. C. Smyrk et al., “Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer,” American Journal of Gastroenterology, vol. 102, no. 8, pp. 1646–1653, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. G. M. Fiedler, A. B. Leichtle, J. Kase et al., “Serum peptidome profiling revealed platelet factor 4 as a potential discriminating peptide associated with pancreatic cancer,” Clinical Cancer Research, vol. 15, no. 11, pp. 3812–3819, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Honda, Y. Hayashida, T. Umaki et al., “Possible detection of pancreatic cancer by plasma protein profiling,” Cancer Research, vol. 65, no. 22, pp. 10613–10622, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. J. M. Koomen, L. N. Shih, K. R. Coombes et al., “Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins,” Clinical Cancer Research, vol. 11, no. 3, pp. 1110–1118, 2005. View at Google Scholar · View at Scopus
  24. J. Koopmann, Z. Zhang, N. White et al., “Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry,” Clinical Cancer Research, vol. 10, no. 3, pp. 860–868, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Safi, W. Schlosser, G. Kolb, and H. G. Beger, “Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms,” Journal of Gastrointestinal Surgery, vol. 1, no. 2, pp. 106–112, 1997. View at Google Scholar · View at Scopus
  26. H. Narimatsu, H. Iwasaki, F. Nakayama et al., “Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients,” Cancer Research, vol. 58, no. 3, pp. 512–518, 1998. View at Google Scholar · View at Scopus
  27. C. A. Iacobuzio-Donahue, A. Maitra, M. Olsen et al., “Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays,” American Journal of Pathology, vol. 162, no. 4, pp. 1151–1162, 2003. View at Google Scholar · View at Scopus
  28. H. Han, D. J. Bearss, L. W. Browne, R. Calaluce, R. B. Nagle, and D. D. Von Hoff, “Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray,” Cancer Research, vol. 62, no. 10, pp. 2890–2896, 2002. View at Google Scholar · View at Scopus
  29. B. Ryu, J. Jones, N. J. Blades et al., “Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression,” Cancer Research, vol. 62, no. 3, pp. 819–826, 2002. View at Google Scholar · View at Scopus
  30. R. M. Caprioli, T. B. Farmer, and J. Gile, “Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS,” Analytical Chemistry, vol. 69, no. 23, pp. 4751–4760, 1997. View at Google Scholar · View at Scopus
  31. S. A. Schwartz, R. J. Weil, R. C. Thompson et al., “Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry,” Cancer Research, vol. 65, no. 17, pp. 7674–7681, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Stoeckli, P. Chaurand, D. E. Hallahan, and R. M. Caprioli, “Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues,” Nature Medicine, vol. 7, no. 4, pp. 493–496, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Ehmann, K. Felix, D. Hartmann et al., “Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling,” Pancreas, vol. 34, no. 2, pp. 205–214, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Guo, W. Wang, P. Liao et al., “Identification of serum biomarkers for pancreatic adenocarcinoma by proteomic analysis,” Cancer Science, vol. 100, no. 12, pp. 2292–2301, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Frulloni, C. Lunardi, R. Simone et al., “Identification of a novel antibody associated with autoimmune pancreatitis,” The New England Journal of Medicine, vol. 361, no. 22, pp. 2135–2142, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Yan, S. Tonack, R. Smith et al., “Confounding effect of obstructive jaundice in the interpretation of proteomic plasma profiling data for pancreatic cancer,” Journal of Proteome Research, vol. 8, no. 1, pp. 142–148, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. H. L. Huang, T. Stasyk, S. Morandell et al., “Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/MALDI-TOF/TOF and data validation by routine clinical assays,” Electrophoresis, vol. 27, no. 8, pp. 1641–1650, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. R. D. Oleschuk, M. E. McComb, A. Chow et al., “Characterization of plasma proteins adsorbed onto biomaterials by MALDI- TOFMS,” Biomaterials, vol. 21, no. 16, pp. 1701–1710, 2000. View at Publisher · View at Google Scholar · View at Scopus
  39. P. B. Yildiz, Y. Shyr, J. S. M. Rahman et al., “Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer,” Journal of Thoracic Oncology, vol. 2, no. 10, pp. 893–901, 2007. View at Publisher · View at Google Scholar · View at Scopus